Vorinostat

Generic Name: Vorinostat

Brand Names: Zolinza

Drug Type: Small Molecule

Chemical Formula: C_₁₄H_₂₀N_₂O_₃

CAS Number: 149647-78-9

Unique Ingredient Identifier: 58IFB293JI

Background: Vorinostat (rINN) or suberoylanilide hydroxamic acid (SAHA), is a drug currently under investigation for the treatment of cutaneous T cell lymphoma (CTCL), a type of skin cancer, to be used when the disease persists, gets worse, or comes back during or after treatment with other medicines. It is the first in a new class of agents known as histone deacetylase inhibitors. A recent study suggested that vorinostat also possesses some activity against recurrent glioblastoma multiforme, resulting in a median overall survival of 5.7 months (compared to 4 - 4.4 months in earlier studies). Further brain tumor trials are planned using combinations of vorinostat with other drugs.

Indication: 用于治疗加重、持续和复发或用两种全身性药物治疗后无效的T细胞淋巴瘤(CTCL, 一种非霍奇金淋巴瘤)。

Associated Conditions: Cutaneous T-Cell Lymphoma Recurrent, Persistent Cutaneous T-Cell Lymphoma, Progressive Cutaneous T-cell lymphoma

Associated Therapies: -

Clinical Trials

Bortezomib and Vorinostat in Treating Patients With Multiple Myeloma Who Have Undergone Autologous Stem Cell Transplant

Phase 2

Completed

Conditions: DS Stage I Plasma Cell Myeloma
DS Stage III Plasma Cell Myeloma
DS Stage II Plasma Cell Myeloma

Interventions: Drug: Bortezomib
Drug: Vorinostat

First Posted Date: 2009-02-10

Last Posted Date: 2017-05-09

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 31

Registration Number: NCT00839956

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Study of the Combination of Vorinostat and Radiation Therapy for the Treatment of Patients With Brain Metastases

Phase 1

Completed

Conditions: Brain Metastases

Interventions: Drug: Vorinostat
Radiation: Radiation Therapy

First Posted Date: 2009-02-09

Last Posted Date: 2016-11-29

Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University

Target Recruit Count: 17

Registration Number: NCT00838929

Locations: 🇺🇸
The University of Texas Southwestern Medical Center, Dallas, Texas, United States
🇺🇸
Thomas Jefferson University, Philadelphia, Pennsylvania, United States

Vorinostat Plus Radiation Therapy in Pancreatic Cancer

Phase 1

Terminated

Conditions: Pancreatic Cancer

Interventions: Radiation: Chemoradiation (Radiation Therapy)
Drug: Vorinostat

First Posted Date: 2009-01-29

Last Posted Date: 2012-02-28

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 3

Registration Number: NCT00831493

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Vorinostat in Combination With Palliative Radiotherapy for Patients With Non-Small Cell Lung Cancer

Phase 1

Completed

Conditions: Non-Small Cell Lung Cancer (NSCLC)

Interventions: Drug: Vorinostat
Radiation: Radiotherapy

First Posted Date: 2009-01-14

Last Posted Date: 2020-11-20

Lead Sponsor: Yale University

Target Recruit Count: 17

Registration Number: NCT00821951

Locations: 🇺🇸
Yale University School of Medicine, New Haven, Connecticut, United States

Bortezomib and Vorinostat in Treating Patients With High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia

Phase 2

Terminated

Conditions: Myelodysplastic Syndrome
Leukemia

Interventions: Drug: bortezomib
Drug: vorinostat

First Posted Date: 2009-01-08

Last Posted Date: 2017-12-28

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 16

Registration Number: NCT00818649

Locations: 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States

Dasatinib and Vorinostat in Treating Patients With Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia or Acute Lymphoblastic Leukemia

Phase 1

Completed

Conditions: Leukemia

First Posted Date: 2009-01-01

Last Posted Date: 2012-07-17

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 5

Registration Number: NCT00816283

Locations: 🇺🇸
City of Hope Medical Group, Pasadena, California, United States
🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States

Combination of Vorinostat and Bortezomib in Relapsed or Refractory T-Cell Non-Hodgkin's Lymphoma

Phase 2

Terminated

Conditions: Lymphoma

Interventions: Drug: Vorinostat
Drug: Bortezomib

First Posted Date: 2008-12-18

Last Posted Date: 2012-08-07

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 1

Registration Number: NCT00810576

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Vorinostat to Prevent Graft Versus Host Disease Following Reduced Intensity, Related Donor Stem Cell Transplant

Phase 1

Completed

Conditions: Hematologic Malignancies
Graft vs Host Disease

Interventions: Procedure: reduced intensity, related donor stem cell transplant
Drug: tacrolimus (standard GVHD prophylaxis)
Drug: mycophenolate (standard GVHD prophylaxis)
Drug: vorinostat

First Posted Date: 2008-12-18

Last Posted Date: 2014-04-11

Lead Sponsor: Pavan Reddy, MD

Target Recruit Count: 61

Registration Number: NCT00810602

Locations: 🇺🇸
Washington University School of Medicine, St. Louis, Missouri, United States
🇺🇸
University of Michigan Cancer Center, Ann Arbor, Michigan, United States